Background: Owing to the increasing prevalence of obesity and diabetes in Asia, and the paucity of studies, we examined the influence of raised blood glucose and diabetes on cancer mortality risk.
populations, with scarce results from Asia. Among the few Asian studies, positive associations between diabetes and cancers of the pancreas, liver, and colorectum, as well as nonHodgkin lymphoma, have been reported [6, 8, [20] [21] [22] [23] [24] . Given increasing life expectancy and urbanisation [25] , the increasing prevalence of obesity [26] , and the growing prevalence of diabetes in Asian populations [27, 28] , more studies are needed to clarify the evidence of the possible effect of diabetes on cancer mortality in Asia.
The Asia Pacific Cohort Studies Collaboration (APCSC) is a large-scale collaborative project with previous reports on the relationship between diabetes and major causes of death [20] [21] [22] 29] . A systematic analysis of mortality from specific cancers in relation to diabetes and blood glucose in the APCSC has not yet been reported. The aims of the present study are twofold: first, to examine associations between fasting blood glucose levels, diabetes, and sitespecific cancer mortality for which sufficient numbers of fatal events were available for analysis and second, to estimate the population attributable fractions (PAFs) of cancer mortality due to diabetes within countries in the region. These give crude measures of the percentages of deaths that are expected to be due to diabetes, should there be a causal relationship [30] .
materials and methods participating studies
The APCSC is a pooled analysis of individual data from cohort studies conducted in the Asia-Pacific region; details have been published elsewhere [31] . Studies were eligible for inclusion if the following criteria were met: study sample was drawn from the Asia-Pacific region; study was of a prospective cohort design; study had at least 5000 person-years of follow-up. Studies were not eligible if entry was dependent on having a particular medical condition or risk factor. At a minimum, studies must have had data on date of birth or age, sex, blood pressure, and date or age of death. Outcome data included mortality from specific cancers. Cohorts were classified as Asian if study members were recruited from mainland China, Hong Kong, Japan, Korea, Singapore, South Korea, Taiwan, or Thailand and as Australasian if from Australia or New Zealand. This classification largely represents a dichotomy by ethnicity into Asians and non-Asians.
baseline assessment
Study participants' diabetes status were determined on the basis of selfreported history of diabetes or by applying the World Health Organization (WHO) diagnostic criteria to blood glucose levels at baseline [32] . Diabetes status according to glucose levels was positive if fasting whole blood glucose was ‡6.1 mmol/l (110 mg/dl) or plasma glucose ‡7 mmol/l (126 mg/dl) or if non-fasting whole blood glucose was ‡10 mmol/l (180 mg/dl) or plasma glucose ‡11.1 mmol/l (200 mg/dl) (information on glucoselowering medication not available). All data on cigarette smoking were self-reported as either current smoker or nonsmoker at the time of study entry. Height and weight were ascertained from direct measurements; body mass index (BMI) was calculated as mass in kilograms divided by the square of the height in meters. Systolic blood pressure was measured using a sphygmomanometer. Participants also reported alcohol use habits (current alcohol user/non-alcohol user), exercise habits ('none or almost none' as sedentary lifestyle/'any exercise' as active exercise), and educational attainment (none/at least primary school).
outcomes
Cancer deaths were classified according to the 9th [33] 
statistical analyses
Analyses were restricted to participants aged ‡20 years at the time of the baseline survey with complete data on diabetes status and site-specific cancer mortality. Cox proportional hazards regression models, stratified by study cohort and sex, and adjusted for age, were used to compute hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for those with and without diabetes, as well as for those with various fasting serum glucose levels. Further adjustments were made in multivariable models that included a priori potential confounding variables: BMI, height [35] , education, smoking status, and alcohol use at baseline. Statistical significance of effect modification across groups defined by geographical area (Asia and Australasia) and sex was tested using the likelihood ratio test [30] . Differences between region and sex were tested for statistical significance using likelihood ratio tests. The PAFs for mortality from sitespecific cancer mortality due to diabetes were calculated for each of the countries in the APCSC using previously published prevalence estimates of diabetes that were adjusted to a world standard population [36] by the formula [30] :
PAF=100·prevalence·ðHR21Þ=½ 100+prevalence·ðHR21Þ:
To explore the possibility of participants with a pre-existing malignancy (e.g. pancreatic cancer) at the time of study entry contributing to the analyses, and potentially attenuating the diabetes-cancer relation (i.e. reverse causality), deaths from cancer in the first 2 years of follow-up were excluded ('left censored') in a sensitivity analysis. In doing so, we reasoned that most deaths due to subclinical malignancy at study entry would have occurred during the first 2 years.
Trends were explored through analyses of fasting serum glucose levels according to tertiles (<4.8, 4.8-5.4, and >5.4 mmol/l). Trends were tested for statistical significance using likelihood ratio tests. All statistical analyses were carried out using STATA version 10.1 for Windows (StataCorp, College Station, TX).
results
A total of 44 studies involving 600 443 participants were recruited to the APCSC by the end of 2006 [31] . Figure 1 shows the selection process of the analytical sample for this study. Information on diabetes at baseline and site-specific cancer mortality was available from 36 of the 44 eligible studies involving 367 361 participants, of whom 41% were female, 74% were Asian, and 6.4% had type 2 diabetes mellitus at study entry (Table 1) . A summary of the characteristics of the included studies are shown in Table 1 . The median follow-up time was 4.0 years and the mean age of participants was 48 years. Participants from the Australasian cohorts were older than those from Asian cohorts. During mortality follow-up, a total of 2 223 958 person-years of follow-up gave rise to 17 413 deaths, of which 5992 were ascribed to cancer (31% female, 51% Asian).
study baseline characteristics
Of the 367 361 participants, 23 560 (24% female, 80% Asian) were classified as having diabetes at baseline. Both Asian and Australasian participants with diabetes were older and had higher levels of BMI, systolic blood pressure, total cholesterol, and triglycerides in both Asia and Australasia. Those from either region with diabetes were also more likely to be male, physically inactive, and have lower levels of education.
outcomes
The age-adjusted, sex, and study stratified HR for death from all cancers was 1.23 (95% CI 1.12, 1.35) for individuals with diabetes compared with individuals without diabetes (Table 3) . This remained largely unchanged after 2-year left-censoring (HR 1.19; 95% CI 1.06, 1.32). Additional adjustment for BMI, height, education, smoking, and alcohol use had no material effect on the magnitude of the diabetes-cancer association. Analysis of the diabetes-cancer association by sex and region showed no evidence of any difference (P-value for interaction >0.1). For mortality from specific cancers, diabetes was associated with an increased risk of cancers of the liver (HR 1.51; 95% CI: 1.19, 1.91) and pancreas (HR 1.78; 95% CI: 1.20, 2.65), compared with those without diabetes (Table 3) . These also persisted after 2-year left-censoring: HR 1.52 (95% CI: 1.15, 2.01) and HR 1.66 (95% CI: 1.04, 2.63), respectively. An increase in the risk of mortality from colorectal cancer was also observed both before and after left-censoring: HR 1.32 (95% CI: 0.98, 1.78) and HR 1.34 (95% CI: 0.96, 1.87), respectively.
Additional analyses were carried out for diabetes at baseline among individuals with cancer mortality with at least 8 years of follow-up. Information on diabetes at baseline and sitespecific cancer mortality was reduced to 15 of the 44 eligible studies involving 95 979 participants, of whom 53% were female, 30% were Asian, and 4.4% had type 2 diabetes mellitus at study entry ( Table 2 ). The new median follow-up time was 9.1 years and the mean age of participants was 50 years. During this longer mortality follow-up, 3135 deaths were ascribed to cancer.
The age-adjusted, sex and study stratified HR for death from all cancers was 1.31 (95% CI: 1.13, 1.51) for individuals with diabetes compared with individuals without diabetes (Table 4) . Additional adjustment for BMI, height, education, smoking, and alcohol use had no substantial effect on the magnitude of the diabetes-cancer association. For mortality from specific cancers, diabetes was associated with an increased risk of cancers of the colorectum (HR 1.50; 95% CI: 1.03, 2.18), liver (HR 2.14; 95% CI: 1.08, 4.25), and pancreas (HR 1.85; 95% (Table 4 ). In addition, diabetes was associated with an increased risk of cancers of the stomach among those with longer follow-up period (HR 1.90; 95% CI: 1.17, 3.08).
association between fasting serum glucose levels and mortality from cancer Fasting serum glucose levels were available from 202 681 participants with a total of 1490 cancer deaths, of whom 8% (16 439/202 682) were classified as having diabetes. Based on this smaller subsample, there were no significant linear associations between glucose levels and all-cause cancer mortality (P for trend = 0.39; Table 5 ) or with any of the site-specific cancers. There was, however, some evidence of a weak positive association with liver cancer (P-value for trend = 0.06) ( Table 5 ). Analysis of trend in those who died from melanoma and multiple myeloma was not possible due to insufficient numbers. PAFs of cancer mortality due to diabetes Figure 2 shows the PAF of mortality from specific cancers that seem to have notable associations with diabetes in the APCSC: pancreas, liver, and colorectum. These PAFs differed substantially across the Asia-Pacific region and were generally higher for Asia than Australasia (Figure 2) . Overall, the PAF ranged from 3.1% to 7.3% for pancreatic cancer, 2.0% to 4.9% for liver cancer, and 1.3% to 3.1% for colorectal cancer.
discussion
To our knowledge, the present study is the first to systematically examine the associations between diabetes and mortality from specific cancers for the diverse populations of the Asia-Pacific region. The results from our large collaborative study indicate that individuals with diabetes have an approximately 20% greater risk of mortality from all-cause cancer compared with those without the condition. Specifically, diabetes is independently associated with mortality from pancreatic, liver, and, possibly, colorectal cancers. These associations did not vary by region or by sex and were adjusted for BMI, height, education, smoking, and alcohol use. The majority of cases of diabetes in this report are likely to be type 2 diabetes but an undetermined proportion may have diabetes secondary to pancreatic disease and some will have type 1 diabetes especially in the non-Asian cohorts.
We found a nearly 78% increased risk of death from pancreatic cancer for those with diabetes, which is comparable with other reports [6, 13, 14, 16, 20, 37] , and a previous meta-analysis [38] . Other studies have also shown abnormal glucose metabolism to be associated with pancreatic cancer mortality [12, 37] . Though our findings suggest diabetes to be Restricted to studies with median follow-up of ‡8 years and participants with information on history of diabetes or blood glucose levels at baseline and sitespecific cancer mortality. SD, standard deviation; ANHF, Australian National Heart Foundation; EGAT, Electricity Generating Authority of Thailand. a risk factor for pancreatic cancer, the diabetic state is also a potential consequence of pancreatic malignancy [24, [38] [39] [40] [41] .
The earlier meta-analysis reported a 50% lower excess risk ratio of pancreatic cancer for individuals with >5 year history of diabetes, compared with those with a shorter duration of diabetes [38] . Recent studies have also shown that onset of diabetes mellitus of <2 years of duration was more prevalent for patients with pancreatic cancer and, therefore, more likely to be induced by malignancy [24, 39] . Our finding of a 50% increased risk of liver cancer mortality for those with diabetes, compared with those without, is consistent with previous reports [6, [13] [14] [15] 42] . Our results also showed a marginally non-significant trend in risk of liver cancer mortality from fasting serum glucose levels (P-value for trend = 0.06). Previous studies [6, 14, [43] [44] [45] as well as a meta-analysis [46] have shown increased risk of colorectal cancer mortality for those with diabetes as suggested in the present study as a possible 30% increased risk of colorectal cancer mortality upon participants with diabetes.
plausible mechanisms
It has been suggested that the increased risk of cancer mortality for those with type 2 diabetes might reflect metabolic and hormonal changes of compensatory hyperinsulinaemia and elevated levels of insulin-like growth factors (IGFs) in response to reduced insulin sensitivity [8, 37, [47] [48] [49] . In this regard, IGF-1 has been shown to stimulate cellular proliferation in the pancreas, liver, and colon [48] [49] [50] . In addition, increased levels of circulating insulin may activate IGF-1 receptor and thereby promote cellular growth and cell cycle progression Restricted to studies with median follow-up of ‡8 years and participants with information on history of diabetes or blood glucose levels at baseline and site-specific cancer mortality. b Hazard ratios are age adjusted, sex, and study stratified.
APCSC, Asia Pacific Cohort Studies Collaboration; CI, confidence interval. * P-value < 0.05. **P-value = 0.01. ***P-value < 0.0001. Annals of Oncology original article [8, 37, 47] . Glucose-lowering therapy, such as exogenous insulin, has been shown to increase cancer risk in a large retrospective cohort study [51] . In these diabetic patients, glucose-lowering therapies with sulphonylurea drugs or insulin were associated with increased cancer risk, as compared with treatment with metformin. In the subjects on insulin, the HR for solid tumour incidence was 1.42 and for pancreatic cancers 4.63, these conditions occurring in <2.0% and <0.2% of cases, respectively. These were a multiplicity of confounders and no causal association can be assumed [51] . The present study, however, did not have information regarding glucose-lowering medications and our reported results may misrepresent the strength of the overall diabetes-cancer association. Similar to the diabetes-pancreatic cancer association, plausible biological mechanisms for the diabetes-liver cancer association may also involve glucose-lowering therapy. Donadon et al. have reported an approximately threefold increased risk of hepatocellular carcinoma for individuals with diabetes on insulin or sulphonylurea treatment [52] . Another putative pathway between diabetes and liver cancer is the occurrence of fatty liver disease. Non-alcoholic fatty liver disease can progress to non-alcoholic steatohepatitis, which may develop subsequently into irreversible cirrhosis, and ultimately hepatocellular carcinoma [53] .
strengths and limitations
The key strengths of the APCSC include its prospective design, its capacity to adjust for several possible confounders, and its large sample size, which allows reliable estimates of associations with deaths from rare cancers to be estimated. One limitation is that information regarding duration of diabetes was not available. Instead, to explore the possibility of reverse causality, the data were 2-year left-censored, with a negligible effect on the original estimates. Given the long latent period between diabetes onset and death from cancer, it is possible that left-censoring the data by 2 years was insufficient to fully eliminate the effects of reverse causality. In this study, the median follow-up time available for analysis was only 4 years duration, so we were unable to explore this issue further. This relatively short median duration of follow-up might not capture mortality from specific cancers that have longer average survival periods. Information regarding cancer incidence, rather than mortality, would be more useful for assessing cancers with low fatality rates (such as prostate cancer) as a smaller proportion of incidence of such cancers would be included in an analysis of cancer mortality alone. There is certainly a distinction between whether diabetes may cause cancer and whether diabetes may increase individual risk of mortality once a particular cancer is acquired-the present study is limited to exploring the latter question as only cancer mortality data were collected. We are, therefore, unable to determine to what extent the increased risk of cancer mortality represents an aetiological role for diabetes or an early manifestation or consequence of cancer.
Another limitation of this study is the diagnostic criteria used for diabetes. While some participants had provided selfreported history of diabetes, approximately two-thirds (65%) of the analytical sample had only laboratory measurements of blood glucose levels to identify their diabetes status. Sole reliance on records of blood glucose levels, without information on self-reported history of diabetes or medication history, might underestimate the true effect of diabetes on cancer mortality as the dataset does not preclude blood glucose levels within normal ranges to be the outcomes of glucose-lowering treatment. The effects of misclassification as such would be conservative and alter the observed effect towards null. However, misclassification of self-reported diabetes may also alter the observed effect away from null as certain participants who reported themselves as 'non-diabetic' may have elevated glucose levels if blood samples were not taken from them during the study. Moreover, the effects of glucose-lowering treatment on normalising blood glucose levels, leading to a misclassification of someone with diabetes as non-diabetic, may be more pronounced among those with diabetes of longer duration, which may have a different relation with cancer mortality than diabetes of shorter duration, thereby making prediction of the direction of misclassification bias difficult. original article
Annals of Oncology
Lastly, some significant associations reported in the present study may be due to chance alone, given the large number of statistical tests carried out for 17 specific cancer end points.
Our comparisons of glucose categories also have potential misclassification issues. Individuals in the normoglycaemic group could have had diabetes since, for those analyses, we were not able to identify individuals who were treated with glucose-lowering therapy. Such misclassifications will attenuate the dose-response relationship between fasting serum glucose levels and liver cancer mortality reported in this study. Finally, the possibility of residual confounding remains. We adjusted for BMI but not measures of central obesity that might be more strongly related to some cancers. In particular, heavy alcohol consumption is associated both with diabetes and with cancers of the liver and colorectum, but our measure of alcohol intake was crude and unable to differentiate between amount, type, and duration of alcohol consumed.
conclusions
The present study adds to the growing body of literature concerning the long-term co-morbidities of diabetes and provides insight into future patterns of diabetes-related cancer mortality. Our findings suggest that diabetes is positively associated with cancer mortality for both Asian and Australasian populations. The relative effect of diabetes on the mortality risk from specific cancers for Asian populations is comparable with those for the largely Caucasian populations of Australasia. Given the increasing diabetes epidemic in both regions [54] , and if the associations were causal, mortality from pancreatic, liver, and, possibly, colorectal cancers may be expected to rise, given that these cancers had the greatest percentage of deaths explained by diabetes. The large number of people living in Asia, particularly China, suggests that this will be a public health problem of importance. Concerted interventions that target the control and reduction of type 2 diabetes in populations of the Asia-Pacific region may have considerable benefits on reducing mortality from cancer, in addition to that from other chronic illnesses. 
